Hannah Slater

The expert from the CUNY School of Medicine spoke about a recent study which indicated that Hispanic adults trust a wide variety of health information sources, suggesting the need for targeted information.

The dose escalation and expansion study is evaluating the safety and tolerability of ONCR-177 in patients with cancer and determining the recommended phase 2 dose.

Researchers were able to establish possible mechanisms that may contribute to racial differences in incidence, patterns of presentation, and survival in patients with DLBCL with African ancestry.

Researchers in Canada launched a phase 3 trial of IMM-101, titled CCTG IC.8, with the hope of strengthening the immune system of patients with cancer.

The committee voted 12-0 in favor of the demonstrated benefit of belantamab mafodotin as monotherapy outweighing the risks for patients with relapsed or refractory multiple myeloma who have received at least 4 prior therapies.

FACT-Leu was found to be a suitable outcome measure for patients not eligible for intensive therapy in acute myeloid leukemia clinical trials.

A study of patients with cancer suspected of having COVID-19 indicated that the death rate at 30 days after diagnosis is high, both in patients with and without documented SARS-CoV-2 infection on RT-PCR.

The co-leader of the NCI Center for Cancer Research Liver Cancer Program discussed the clinical utility of the blood test and how it could potentially change liver cancer diagnoses moving forward.

The study showed that the addition of atezolizumab to bevacizumab, paclitaxel, and carboplatin as a front-line treatment in women with newly diagnosed advanced stage ovarian cancer did not meet its primary endpoint of progression-free survival.

The study results confirmed that the triple-negative breast cancers emergence among young compared with elderly patients can be completely different entities.

Researchers suggested that the use of the oral agent over a prolonged period of time should now be considered part of the overall treatment plan in acute promyelocytic leukemia.

AYAs with cancer indicated that they value early information about the risks of late effects and infertility, though many patients also felt that they had not been given this high-quality information.

Findings suggested that conventional mammography screening performance metrics underestimate the interval cancer rate of a mammography screening episode.

Researchers found that dense allele-specific DNA methylation (ASM) mapping in normal samples plus cancer samples reveals possible candidate regulatory sequence polymorphisms (rSNPS) that are difficult to find by other approaches.

The FDA accepted and granted priority review to a supplemental biologics license application for pembrolizumab as monotherapy for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma.

The president and CEO of Cancer Treatment Centers of America highlighted the importance in caring for patients with cancer even in the midst of the coronavirus disease 2019 (COVID-19) pandemic.

Researchers highlighted the importance of recognizing the environmental and biological factors that contribute to the development of PTSD, which can help inform clinical care and potentially reduce PTSD comorbidity.

The FDA has approved an oral combination of decitabine and cedazuridine for adult patients with myelodysplastic syndromes.

In this study, researchers observed no association between black race and the risk of SREs and overall mortality in men with bone metastatic castration-resistant prostate cancer.

In this study, neutrophil extracellular traps were found to prompt the lethal blood clots and inflammation that occur in some patients with COVID-19.

The study of temsirolimus and cetuximab versus temsirolimus alone in patients with recurrent or metastatic cetuximab-resistant head and neck cancer did not meet its primary end point of improved progression-free survival.

Patients with chemotherapy-naïve, locally advanced, or metastatic non-small cell lung cancer who were treated with tiragolumab plus an anti-PD-L1 agent showed better efficacy versus single-agent checkpoint inhibitor therapy alone.

This study found that Hispanic adults trust a wide variety of health information sources, indicating the need for targeted and tailored information from healthcare providers.

However, when followed by immunomodulatory drugs, researchers found that autologous stem cell transplant can be safely used in this patient population, regardless of CHIP status.

In our liver cancer quiz, you’ll get a chance to test your knowledge on the use of viral exposure signatures in detecting hepatocellular carcinoma.

The findings support ctDNA testing in patients who are undergenotyped at the time of diagnosis and as a primary option at the time of progression on targeted therapies.

In this open-label, randomized, phase 2 trial, treatment with trastuzumab deruxtecan led to significant improvements in response and overall survival in patients with HER2-positive gastric cancer.

Fam-trastuzumab deruxtecan-nxki (Enhertu) showed favorable clinical activity with a high objective response rate and durable responses in patients with HER2-mutated non-small cell lung cancer.

The study demonstrated modest survival benefits in patients with extensive-stage small cell lung cancer who received the combination of pembrolizumab and etoposide plus platinum (EP).

Researchers have developed a new blood test that may help in identifying individuals who are likely to develop hepatocellular carcinoma.